Keyword: Ultomiris (ravulizumab-cwvz)
Despite an activist investor knocking at the door, Alexion is confident its Soliris switch campaign and pipeline are proving doubters wrong.
With its campaign to switch patients from blockbuster Soliris to Ultomiris going well, Alexion is swinging for the fences with a late-stage ALS study.
Alexion is facing a competitor to its blockbuster Soliris amid a switching campaign to a follow-up drug. But analysts so far aren't concerned.
Alexion, amidst a strategy shift to pipeline building, has said no to an activist investor's call to pursue a "proactive" sale.
Alexion is working to switch patients from Soliris to its newer Ultomiris.
Alexion is pushing hard to get patients on its blockbuster Soliris over to a follow-up drug, but the older med's sales are still hanging in there.
Alexion's campaign to switch patients from blockbuster Soliris to a follow-up drug has gone according to plan. A new indication will help even more.
Investors are running scared after a patent challenge from Amgen hit Alexion’s bestselling Soliris—but is it that big of a deal?
9. Alexion Pharmaceuticals
Rumors that Amgen could buy Alexion have been floating around for more than a year. Now, they’ve resurfaced, to the delight of Wall Street analysts.